TY - JOUR
T1 - Generation of two induced pluripotent stem cell lines and the corresponding isogenic controls from Parkinson's disease patients carrying the heterozygous mutations c.815G > A (p.R272Q) or c.1348C > T (p.R450C) in the RHOT1 gene encoding Miro1
AU - Chemla, Axel
AU - Arena, Giuseppe
AU - Onal, Gizem
AU - Walter, Jonas
AU - Berenguer-Escuder, Clara
AU - Grossmann, Dajana
AU - Grünewald, Anne
AU - Schwamborn, Jens C.
AU - Krüger, Rejko
N1 - Funding Information:
AC is supported by the Luxembourg Fonds National de Recherche (FNR) within the framework of the PARK-QC DTU (PRIDE17/12244779/PARK-QC). Work of GA is supported by the FNR, grant number C21/BM/15850547/PINK1-DiaPDs. Work of AG was supported by the FNR within the ATTRACT program (Model-IPD, FNR9631103). RK obtained funding from the FNR PEARL Excellence Programme [FNR/P13/6682797], the Michael J. Fox Foundation, and the European Union's Horizon2020 research and innovation program (WIDESPREAD; CENTRE-PD; grant agreement no. 692320). In addition, RK, AG and GA were supported by the FNR CORE grant MiRisk-PD (C17/BM/11676395).
Funding Information:
AC is supported by the Luxembourg Fonds National de Recherche (FNR) within the framework of the PARK-QC DTU (PRIDE17/12244779/PARK-QC). Work of GA is supported by the FNR, grant number C21/BM/15850547/PINK1-DiaPDs. Work of AG was supported by the FNR within the ATTRACT program (Model-IPD, FNR9631103). RK obtained funding from the FNR PEARL Excellence Programme [FNR/P13/6682797], the Michael J. Fox Foundation , and the European Union’s Horizon2020 research and innovation program (WIDESPREAD; CENTRE-PD ; grant agreement no. 692320 ). In addition, RK, AG and GA were supported by the FNR CORE grant MiRisk-PD ( C17/BM/11676395 ).
Publisher Copyright:
© 2023 The Author(s)
PY - 2023/9
Y1 - 2023/9
N2 - Fibroblasts from two Parkinson's disease (PD) patients carrying either the heterozygous mutation c.815G > A (Miro1 p.R272Q) or c.1348C > T (Miro1 p.R450C) in the RHOT1 gene, were converted into induced pluripotent stem cells (iPSCs) using RNA-based and episomal reprogramming, respectively. The corresponding isogenic gene-corrected lines have been generated using CRISPR/Cas9 technology. These two isogenic pairs will be used to study Miro1-related molecular mechanisms underlying neurodegeneration in relevant iPSC-derived neuronal models (e.g., midbrain dopaminergic neurons and astrocytes).
AB - Fibroblasts from two Parkinson's disease (PD) patients carrying either the heterozygous mutation c.815G > A (Miro1 p.R272Q) or c.1348C > T (Miro1 p.R450C) in the RHOT1 gene, were converted into induced pluripotent stem cells (iPSCs) using RNA-based and episomal reprogramming, respectively. The corresponding isogenic gene-corrected lines have been generated using CRISPR/Cas9 technology. These two isogenic pairs will be used to study Miro1-related molecular mechanisms underlying neurodegeneration in relevant iPSC-derived neuronal models (e.g., midbrain dopaminergic neurons and astrocytes).
UR - http://www.scopus.com/inward/record.url?scp=85162887901&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/37364399
U2 - 10.1016/j.scr.2023.103145
DO - 10.1016/j.scr.2023.103145
M3 - Article
C2 - 37364399
SN - 1873-5061
VL - 71
JO - Stem Cell Research
JF - Stem Cell Research
M1 - 103145
ER -